NVCT has 36-month beta value of 0.44. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NVCT is 6.95M, and currently, short sellers hold a 11.84% ratio of that float. The average trading volume of NVCT on May 02, 2024 was 95.91K shares.
NVCT) stock’s latest price update
Nuvectis Pharma Inc (NASDAQ: NVCT)’s stock price has gone rise by 9.38 in comparison to its previous close of 6.08, however, the company has experienced a -0.89% decrease in its stock price over the last five trading days. InvestorPlace reported 2024-04-02 that What has been the top-performing stock so far of 2024? If you had said server installer Super Micro Computer (NASDAQ: SMCI ), that would be a great answer.
NVCT’s Market Performance
Nuvectis Pharma Inc (NVCT) has seen a -0.89% fall in stock performance for the week, with a -16.25% decline in the past month and a -8.78% plunge in the past quarter. The volatility ratio for the week is 8.67%, and the volatility levels for the past 30 days are at 8.57% for NVCT. The simple moving average for the past 20 days is -5.41% for NVCT’s stock, with a -33.84% simple moving average for the past 200 days.
Analysts’ Opinion of NVCT
Many brokerage firms have already submitted their reports for NVCT stocks, with Ladenburg Thalmann repeating the rating for NVCT by listing it as a “Buy.” The predicted price for NVCT in the upcoming period, according to Ladenburg Thalmann is $21 based on the research report published on July 13, 2022 of the previous year 2022.
NVCT Trading at -19.94% from the 50-Day Moving Average
After a stumble in the market that brought NVCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.34% of loss for the given period.
Volatility was left at 8.57%, however, over the last 30 days, the volatility rate increased by 8.67%, as shares sank -19.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.41% lower at present.
During the last 5 trading sessions, NVCT fell by -0.89%, which changed the moving average for the period of 200-days by -56.42% in comparison to the 20-day moving average, which settled at $6.95. In addition, Nuvectis Pharma Inc saw -20.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVCT starting from BENTSUR RON, who purchase 5,000 shares at the price of $10.29 back on Mar 18 ’24. After this action, BENTSUR RON now owns 3,242,484 shares of Nuvectis Pharma Inc, valued at $51,450 using the latest closing price.
BENTSUR RON, the Chairman & CEO of Nuvectis Pharma Inc, purchase 640 shares at $11.08 during a trade that took place back on Oct 10 ’23, which means that BENTSUR RON is holding 3,237,484 shares at $7,091 based on the most recent closing price.
Stock Fundamentals for NVCT
Current profitability levels for the company are sitting at:
- -5.58 for the present operating margin
- -1.91 for the gross margin
The net margin for Nuvectis Pharma Inc stands at -5.42. The total capital return value is set at -1.88. Equity return is now at value -168.51, with -112.45 for asset returns.
Currently, EBITDA for the company is -22.9 million with net debt to EBITDA at 0.84. When we switch over and look at the enterprise to sales, we see a ratio of 24.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.75.
Conclusion
To put it simply, Nuvectis Pharma Inc (NVCT) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
